High TMB Predicts Immunotherapy Benefit in NSCLC [News in Brief]

Ipilimumab–nivolumab combo improves progression-free survival in subset of patients, study shows.

from Cancer via ola Kala on Inoreader https://ift.tt/2H4bdd7
via IFTTT